November 30, 2017 08:49 AM EST

After all the love and money, analysts speculate that J&J may swoop in with a buyout offer for Genmab

John Carroll

Editor & Founder

Genmab Chief Executive Jan van de Winkel doesn’t understate his affection for J&J. When the two companies tied the knot over Darzalex, the CEO described …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

After all the love and money, analysts speculate that J&J may swoop in with a buyout offer for Genmab

John Carroll

Editor & Founder

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Af­ter all the love and mon­ey, an­a­lysts spec­u­late that J&J may swoop in with a buy­out of­fer for Gen­mab

Editor & Founder

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

After all the love and money, analysts speculate that J&J may swoop in with a buyout offer for Genmab